Date | Title | Description | Source |
01.04.2024 | Впервые в мире почку свиньи изменили генетически и пересадил... | Хирурги из США провели человеку трансплантацию почки, полученной из генетически модифицированной сви... | incrussia.... |
08.03.2024 | CAR T-Cell Therapy Market Set for Healthy Growth after COVID... | CHICAGO, UNITED STATES, March 8, 2024 /EINPresswire.com/ -- Astute Analytica, a leading provider of ... | einpresswi... |
08.03.2024 | CRISPR Technology Takes Center Stage at SXSW 2024 for the Fi... | - | globenewsw... |
21.08.2023 | Intellia plays down concerns about accidental germline trans... | Earlier this month, Intellia Therapeutics announced it was scrapping plans to include U.S.-based sit... | statnews.c... |
03.11.2022 | Intellia Therapeutics Announces Third Quarter 2022 Financial... | Presented interim data from the cardiomyopathy arm of NTLA-2001 Phase 1 study demonstrating deep and... | einpresswi... |
12.10.2022 | Gene-editing companies are growing thanks to fast-paced scie... | Marianne Ayala/Insider This story is available exclusively to Insider subscribers. Become an Insider... | businessin... |
16.09.2022 | Another Intellia CRISPR therapy flashes potential for one-ti... | An experimental CRISPR-based treatment from Intellia Therapeutics now has encouraging early clinical... | medcitynew... |
28.02.2022 | Expanded Intellia CRISPR data set up showdown with Pfizer, I... | Eight months after delivering landmark results with one of the first CRISPR clinical trials of its k... | endpts.com... |
15.02.2022 | Biofrontera will yank shares from Nasdaq; Intellia and O... | German biopharma Biofrontera has decided to delist its shares from the Nasdaq and deregiste... | endpts.com... |
26.01.2022 | Well-connected, Gilead-backed biotech gets another stack... | Almost exactly two years after its debut at the 2020 JP Morgan confab — and on the heels of a... | endpts.com... |
26.01.2022 | Digital med company Akili set to go public via Palih... | PureTech sub Akili Interactive — a prescription digital health company and maker of the f... | endpts.com... |
26.01.2022 | CytoDyn fires embattled CEO as its growing chorus of c... | As the first month of 2022 draws to a close, one thing seems to be on everyone’s mind in the biophar... | endpts.com... |
10.01.2022 | Pfizer's $1 billion bet on an ultraprecise CRISPR technology... | Albert Bourla, the CEO of Pfizer. Crystal Cox/Insider This story is available exclusively to Insider... | businessin... |
13.12.2021 | Intellia doses first patient with anti-HAE gene thera... | Gene therapy biotech Intellia Therapeutics has dosed its first patient with genome editing ... | endpts.com... |
04.11.2021 | Intellia Therapeutics Announces Third Quarter 2021 Financial... | Initiated dosing of Cohort 4 in the ongoing Phase 1 study of NTLA-2001; data update from completed d... | marketscre... |
16.09.2021 | FDA accepts Intellia's IND for CRISPR and TCR-T cell the... | Riding the coattails of a massive $600 million cash raise in June, Intellia announced that th... | endpts.com... |
05.07.2021 | Intellia Therapeutics : Announces Closing of $690 Million Pu... | CAMBRIDGE, Mass. - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editin... | marketscre... |
02.07.2021 | Intellia Therapeutics Announces Closing of $690 Million Publ... | CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a lea... | marketscre... |
06.05.2021 | INTELLIA THERAPEUTICS, INC.
Intellia Therapeutics Announces... | Plan to report initial safety and activity data from Phase 1 study of NTLA-2001, a potentially curat... | marketscre... |
08.03.2021 | Editas, Intellia: After Big Sell Off, Is it Time To Buy Gene... | BRAZIL - 2021/02/18: In this photo illustration an Editas Medicine logo seen displayed on a ... [+] ... | forbes.com... |
11.02.2021 | Vertex, Intellia Therapeutics: Gene Editing Stocks To Watch | BRAZIL - 2020/01/13: In this photo illustration the Vertex Pharmaceuticals logo is seen displayed on... | forbes.com... |
28.01.2021 | Intellia, Editas: How Are Gene Editing Stocks Faring? | Gene-editing technology is used to insert, edit, or delete a gene from an organism’s genome, and sho... | forbes.com... |
11.01.2021 | CRISPR, Editas, Intellia: Gene Editing Stocks To Play The Ne... | BRAZIL - 2020/10/29: In this photo illustration the CRISPR Therapeutics logo seen displayed on a ...... | forbes.com... |
05.12.2020 | INTELLIA THERAPEUTICS, INC.
Intellia Therapeutics Announces... | CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a lea... | marketscre... |
05.11.2020 | INTELLIA THERAPEUTICS, INC.
Intellia Therapeutics Announces... | On track to dose first patient by year-end with NTLA-2001 for the treatment of transthyretin amyloid... | marketscre... |
06.08.2020 | INTELLIA THERAPEUTICS, INC.
Intellia Therapeutics Announces... | Submitted first regulatory application to the U.K.’s MHRA to initiate a Phase 1 study of NTLA-2001 f... | marketscre... |
08.06.2020 | INTELLIA THERAPEUTICS, INC.
Intellia Therapeutics : Announc... | CAMBRIDGE - Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on ... | marketscre... |
06.06.2020 | INTELLIA THERAPEUTICS, INC.
Intellia Therapeutics Announces... | CAMBRIDGE, Mass., June 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a lea... | marketscre... |
29.04.2019 | Caribou Biosciences CEO, Rachel Haurwitz will talk CRISPR’s ... | Seven years ago, Rachel Haurwitz finished her last day as a student in the University of California ... | techcrunch... |
29.06.2016 | The biotech IPO feast flags as investors lose their appeti... | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. B... | endpts.com... |
09.06.2016 | CRISPR/Cas9 already is a revolution in molecular biology | As you might expect given the excitement, the last 12-24 months have seen huge upswing in popular in... | medcitynew... |
11.04.2016 | Gene-editing biotech Intellia files for $120 million IPO | Intellia Therapeutics, a biotech company that aims to use a revolutionary gene editing technology to... | statnews.c... |
01.09.2015 | Intellia Therapeutics Lands $70M |
CAMBRIDGE, MA, Intellia Therapeutics has closed a Series B investment round with $70 million in ad... | vcnewsdail... |
01.09.2015 | Daily funding roundup - September 1, 2015 | IDG nabbed $120M; Cequr raised $100M; Cloud Apps Capital Partners bagged $53.7M
Cloud business softw... | vator.tv/n... |
01.09.2015 | Intellia Therapeutics Raises $70m in Series B Funding | Intellia Therapeutics, a Cambridge, MA-based gene-editing company focused on the development of cura... | finsmes.co... |
01.09.2015 | Intellia Therapeutics secures $70M Series B to accelerate CR... | Additional investors included Fidelity Management and Research Company, Janus Capital Management, Fo... | medcitynew... |
11.08.2015 | CRISPR: Editas’ $120M proves it isn’t a bunch of hype. Here ... | But that’s already turned quickly on its head.
Confidence is growing in the technology, as evidenced... | medcitynew... |
13.05.2015 | The Genome Engineering Revolution | Ryan Clarke Contributor
More posts by this contributor
A Third Act For Biofuels
James Hyun Contribut... | techcrunch... |
19.11.2014 | Intellia Therapeutics Closes $15m Series A Financing | Intellia Therapeutics, a Cambridge, MA-based new company formed to develop therapeutic products usin... | finsmes.co... |
18.11.2014 | Intellia Therapeutics Lands $15M in Funding |
CAMBRIDGE, MA, New company formed to develop therapeutic products using CRISPR-Cas9 technology for... | vcnewsdail... |
- | After falling behind gene-editing rivals, Editas just got a ... | Editas Medicine CEO James Mullen Editas Medicine This story is available exclusively to Insider subs... | businessin... |
- | Intellia Therapeutics secures $70M Series B to accelerate CR... | CRISPR-focused companies in the biotech landscape are continuing to grow, and Cambridge-based Intell... | medcitynew... |
- | Big Pharma is waking up to the booming field of gene editing... | Marianne Ayala/Insider This story is available exclusively to Insider subscribers. Become an Insider... | businessin... |
- | CRISPR: Editas’ $120M proves it isn’t a bunch of hype. Here ... | CRISPR/Cas9 gene editing has zoomed to the forefront of the biotech investment scape in the past yea... | medcitynew... |
- | Meet the 12 biotechs pioneering cutting-edge cures that stan... | Intellia Therapeutics is developing CRISPR-based gene-editing medicines that could cure diseases. In... | businessin... |
- | CRISPR/Cas9 already is a revolution in molecular biology | CRISPR/Cas9 genome editing has captured the attention of the popular media, scientific community and... | medcitynew... |
- | How a 30-year-old CEO sold his tiny gene-editing startup to ... | Rewrite Therapeutics CEO Shakked Halperin. Courtesy of Shakked Halperin This story is available excl... | businessin... |